TET2 Antikörper (N-Term)
Kurzübersicht für TET2 Antikörper (N-Term) (ABIN1450172)
Target
Alle TET2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human.
-
Aufreinigung
- Affinity chromatography purified via peptide column
-
Immunogen
- 18 amino acid synthetic peptide near the amino terminus of Human TET2
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- TET2 (Tet Methylcytosine Dioxygenase 2 (TET2))
-
Andere Bezeichnung
- TET2
-
Hintergrund
- TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14 % of patients with JAK2V617F-positive myeloproliferative neoplasms, and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.Synonyms: KIAA1546, Methylcytosine dioxygenase TET2
-
Gen-ID
- 54790
-
NCBI Accession
- NP_001120680
-
Pathways
- Warburg Effekt
Target
-